In the Press
Newsday Business, July 15, 2015: http://www.newsday.com/business/symbiotic-fecal-pill-startup-gets-100g-in-funding-1.10642826
Nature Biotechnology, March 2015: Drugging the gut microbiome http://www.nature.com/nbt/journal/v33/n3/fig_tab/nbt.3161_T1.html
Crain's New York Business News, August 5, 2014: http://www.crainsnewyork.com/article/20140805/HEALTH_CARE/308039985/symbiotic-health-tackles-hospital-acquired-infection
Nature Biotechnology, May 2014: Fecal transplantation poses dilemma for FDA http://www.nature.com/nbt/journal/v32/n5/full/nbt0514-401.html?message-global=remove
NYC MedTech Interview, July 2, 2014: https://www.youtube.com/watch?v=ZuSwIPZOp9M
The Atlantic, December 2, 2013: http://www.theatlantic.com/health/archive/2013/12/after-antibiotics-the-feces-pill-remains/281925/
News & Events
Founders of Symbiotic Health Honored by the Peggy Lillis Foundation's Innovators Award
Brooklyn, NY, October 24,2014 -Symbiotic Health founders Dr.s Gerard Honig and Bruce Hirsch were awarded the Innovators Award at the5th Annual FIGHT C.DIFF Gala hosted by the Peggy Lillis Foundation.
The Peggy Lillis Foundation is building a nationwide Clostridium difficile awareness movement by educating the public, empowering advocates, and shaping policy.
See more at -- http://www.prweb.com/releases/2014/10/prweb12268385.htm
Symbiotic Health wins Best in Show - MidAtlantic BioAngels 1st Pitch Competition
New York, NY, March 9, 2015 – Founder & CEO Gerard Honig
Symbiotic Health Awarded Accelerate Long Island & Long Island Emerging Technologies Fund Seed Funding
Roslyn Heights, NY, July 16, 2015 – Accelerate Long Island and the Long Island Emerging Technologies Fund (LIETF) have announced an investment of $100,000 in Symbiotic Health Inc. The biotechnology startup is dedicated to developing and commercializing bacterial therapeutics for the treatment of Clostridium difficile (C. difficile), a bacterium that causes diarrhea and more-serious intestinal conditions such as colitis that requires prolonged use of antibiotics.
Accelerate Long Island provided a $50,000 grant to Symbiotic Health from its $500,000 Seed Fund, which was established by a grant from New York State Empire State Development awarded by the Long Island Regional Economic Development Council. Jove Equity Partners from the Long Island Emerging Technologies Fund (LIETF) also invested $50,000 in Symbiotic Health, for a total investment of $100,000. Symbiotic Health is the eighth investment to date made by the Accelerate Long Island Seed Fund and the LIETF.
Symbiotic Health Receives Investment from Topspin Partners
New York, NY, August 2015
Symbiotic Health, Inc., leverages the power of naturally occurring gastrointestinal bacteria and viruses (the microbiome) to improve human health based on its proprietary technology for the targeted delivery of therapeutics to the gut using stable oral capsules.
Symbiotic Health has successfully raised series A funding from Top Spin Partners to support its work on the development of the proprietary capsule technology. In connection with the investment, Mr. Leo Guthart and Mr. Steve Winick of Top Spin Partners joined the Board of Directors, along with Dr. Gerard Honig, the Founder and CEO of Symbiotic Health.
Symbiotic Health Announces the Addition of Dr. Kathryn Stein to the Board of Directors
New York, NY, January 2016 —Dr. Gerard Honig, Founder and CEO of Symbiotic Health announces the addition of Dr. Kathryn Stein to the Board of Directors. Dr. Kathryn Stein is an immunologist who has over 30 years of experience in biotechnology as a senior manager at the FDA. Dr. Stein was the first Director of the Division of MonoclonalAntibodies, Office of Therapeutics Research and Review, at the FDA. Dr. Stein was a leader in developing policies to regulate polysaccharide-protein conjugate vaccines, monoclonal antibodies and other recombinant DNA-derived products. In 2002, Dr. Stein joined MacroGenics. As the Senior Vice President she was responsible for establishing the Product Development and Regulatory Affairs, Project Management, Quality and Manufacturing departments.
Dr. Stein received a BA in chemistry from Bard College and a PhD in microbiology and immunology from the Sue Golding Graduate Division of the Albert Einstein College of Medicine. Prior to joining the FDA, she was a post-doctoral Fellow at Harvard with Dr. Harvey Cantor and at NIH with Dr. William Paul.
Symbiotic Health Appoints Chandrabali Ghose, Ph.D as Chief Scientific Officer
New York, NY, August 2015—Dr. Gerard Honig, Founder and CEO of Symbiotic Health announced theaddition of Dr. Chandrabali Ghose to the team as the Chief Scientific Officer. Prior tojoining Symbiotic Health, Dr. Ghose spent the last 8 years, first as a postdoctoral fellow and then a research scientist at the Aaron Diamond AIDS Research Center, an affiliate of Rockefeller University. Dr. Ghose was part of the laboratory of Dr. David D. Ho, where she lead Clostridium difficile team.
Dr. Ghose received her undergraduate education in Biology and Theology from Saint Louis University, splitting her time between the Madrid, Spain and Saint Louis, Missouri campuses. Subsequently, Dr. Ghose moved to New York University where she earned her PhD in Basic Biomedical Sciences from the Department of Microbiology. Her thesis work was performed in the laboratories of Dr. Martin J. Blaser, Chairman of Medicine and Dr. Guillermo I. Perez-Perez, Associate Professor of Microbiology and Medicine. Dr. Ghose did her first postdoctoral fellowship at Harvard Medical School, Boston, in the laboratory of Dr. Edward T. Ryan, Director of Tropical Medicine, Professor of Medicine, Harvard Medical School, and Professor of Immunology and Infectious Diseases, Harvard School of Public Health.
Dr. Ghose has published high-impact peer-reviewed articles and book chapters in the fields of Helicobacter pylori, Vibrio cholerae and Clostridium difficile. Dr. Ghose holds patents on the compositions and methods of prophylaxis and therapy of Clostridium difficile infection.
From 2013-2015, Dr. Ghose was the Chairperson of Research and Development at the C. Diff Foundation, a nonprofit organization committed to raising awareness about C.difficile and the disease it causes, through education and advocacy. Symbiotic Health enters licensing agreement with Rockefeller University to develop and commercialize for the treatment of Clostridium difficile infection
Symbiotic Health Announces the Addition of Vincent Fischetti, Ph.D. to the Scientific Advisory Board
New York, NY, March 2016—Dr. Gerard Honig, Founder and CEO of Symbiotic Health announced the addition of Dr. Vincent Fischetti of Rockefeller University to its Scientific Advisory Board (SAB). "Vince is one of the foremost experts on the use of phage lysins as therapeutics against various bacterial infections” said Dr. Honig Founder and CEO of Symbiotic Health. "We are very fortunate to have Vince on our board and we look towards his extensive knowledge and expertise in this field as we move our Clostridium difficile lysin program forward."
"Vince is a welcome addition to our team and we feel he would provide meaningful insights to our lysin program to treat and prevent CDI " said Dr. Chandrabali Ghose, Chief Scientific Officer of Symbiotic Health. "He is a welcome addition to our team and will contribute greatly to our efforts in developing microbiome therapeutics.” Dr. Fischetti is the Head of the Laboratory of Bacterial Pathogenesis and Immunology at Rockefeller University. Dr. Fischetti is a faculty member in the David Rockefeller Graduate Program and the Tri-Institutional M.D.-Ph.D. Program.